Clinical Trial: Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Double-Blind,2 Dose Group Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI

Brief Summary: The purpose of the study is to evaluate the safety, efficacy and pharmacokinetics of two dose levels of weekly intravenous infusions of recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) for a minimum of 24 weeks in patients diagnosed with MPS VI.

Detailed Summary:
Sponsor: BioMarin Pharmaceutical

Current Primary Outcome: Lysosomal storage disease

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: BioMarin Pharmaceutical

Dates:
Date Received: November 4, 2002
Date Started: September 2000
Date Completion: November 2005
Last Updated: November 2, 2006
Last Verified: November 2006